Skin deep.

June 16, 2017. Same biologic success song, different targeted-protein verse. The ALCANZA trial published last week in Lancet showed improved durable (≥4 months) response rates in cutaneous T-cell lymphoma with brentuximab vedotin (a CD30 antibody-drug conjugate). This RCT enrolled 131 patients with MF or ALCL which failed prior therapy to receive brentuximab vedotin versus physician’s choice of oral MTX or bexarotene for up to 48 weeks. Those randomized to receive brentuximab vedotin had over triple the durable global response rate (56.3%) versus physician’s choice (12.5%, p<0·0001). And if you’re still confused from yesterday about what distinguishes a biologic from other chemical targeted-therapies: here’s an oldie but a goodie.


Popular Posts